{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T16:18:35Z","timestamp":1777047515580,"version":"3.51.4"},"publisher-location":"Singapore","reference-count":69,"publisher":"Springer Singapore","isbn-type":[{"value":"9789813293571","type":"print"},{"value":"9789813293588","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-981-32-9358-8_15","type":"book-chapter","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T17:08:40Z","timestamp":1582564120000},"page":"177-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Associations Between APOE Variants, Tau and \u03b1-Synuclein"],"prefix":"10.1007","author":[{"given":"Elena","family":"Rodriguez-Vieitez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrietta M.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"issue":"7","key":"15_CR1","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/brain\/awy146","volume":"141","author":"JL Robinson","year":"2018","unstructured":"Robinson JL, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141(7):2181\u201393.","journal-title":"Brain"},{"issue":"1","key":"15_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","volume":"16","author":"DJ Irwin","year":"2017","unstructured":"Irwin DJ, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 2017;16(1):55\u201365.","journal-title":"Lancet Neurol"},{"issue":"4","key":"15_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrneurol.2018.9","volume":"14","author":"VL Villemagne","year":"2018","unstructured":"Villemagne VL, et al. Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14(4):225\u201336.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"15_CR4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1474-4422(14)70252-2","volume":"14","author":"VL Villemagne","year":"2015","unstructured":"Villemagne VL, et al. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114\u201324.","journal-title":"Lancet Neurol"},{"issue":"21","key":"15_CR5","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","volume":"30","author":"LK Clinton","year":"2010","unstructured":"Clinton LK, et al. Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30(21):7281\u20139.","journal-title":"J Neurosci"},{"issue":"5","key":"15_CR6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/gim.2015.117","volume":"18","author":"C Cauwenberghe Van","year":"2016","unstructured":"Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18(5):421\u201330.","journal-title":"Genet Med"},{"key":"15_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41577-018-0051-1","volume":"18","author":"Y Shi","year":"2018","unstructured":"Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat Rev Immunol. 2018;18:759\u201372.","journal-title":"Nat Rev Immunol"},{"issue":"Pt 4","key":"15_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1046\/j.1469-1809.1999.6340301.x","volume":"63","author":"RM Corbo","year":"1999","unstructured":"Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE\u22174 a \u2018thrifty\u2019 allele? Ann Hum Genet. 1999;63(Pt 4):301\u201310.","journal-title":"Ann Hum Genet"},{"issue":"5","key":"15_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.tins.2014.03.001","volume":"37","author":"DA Raichlen","year":"2014","unstructured":"Raichlen DA, Alexander GE. Exercise, APOE genotype, and the evolution of the human lifespan. Trends Neurosci. 2014;37(5):247\u201355.","journal-title":"Trends Neurosci"},{"key":"15_CR10","doi-asserted-by":"crossref","first-page":"974361","DOI":"10.4061\/2011\/974361","volume":"2011","author":"V Leduc","year":"2011","unstructured":"Leduc V, et al. Function and comorbidities of apolipoprotein e in Alzheimer\u2019s disease. Int J Alzheimers Dis. 2011;2011:974361.","journal-title":"Int J Alzheimers Dis"},{"issue":"1","key":"15_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1172\/JCI113849","volume":"83","author":"HG Kraft","year":"1989","unstructured":"Kraft HG, et al. Changes of genetic apolipoprotein phenotypes caused by liver-transplantation\u00a0\u2013 implications for apolipoprotein synthesis. J Clin Investig. 1989;83(1):137\u201342.","journal-title":"J Clin Investig"},{"issue":"1","key":"15_CR12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1172\/JCI115288","volume":"88","author":"MF Linton","year":"1991","unstructured":"Linton MF, et al. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest. 1991;88(1):270\u201381.","journal-title":"J Clin Invest"},{"issue":"5","key":"15_CR13","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00109-018-1632-y","volume":"96","author":"M Kockx","year":"2018","unstructured":"Kockx M, Traini M, Kritharides L. Cell-specific production, secretion, and function of apolipoprotein E. J Mol Med (Berl). 2018;96(5):361\u201371.","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"15_CR14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/0005-2760(87)90295-5","volume":"917","author":"RE Pitas","year":"1987","unstructured":"Pitas RE, et al. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta. 1987;917(1):148\u201361.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"15_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nrn2620","volume":"10","author":"G Bu","year":"2009","unstructured":"Bu G. Apolipoprotein E and its receptors in Alzheimer\u2019s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10(5):333\u201344.","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"15_CR16","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1172\/JCI112645","volume":"78","author":"RE Gregg","year":"1986","unstructured":"Gregg RE, et al. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest. 1986;78(3):815\u201321.","journal-title":"J Clin Invest"},{"issue":"6","key":"15_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038013","volume":"7","author":"KR Wildsmith","year":"2012","unstructured":"Wildsmith KR, et al. In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. PLoS One. 2012;7(6):e38013.","journal-title":"PLoS One"},{"issue":"5","key":"15_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1067\/mlc.2002.129066","volume":"140","author":"K Ikewaki","year":"2002","unstructured":"Ikewaki K, et al. Comparative in vivo metabolism of apolipoproteins E2 and E4 in heterozygous apoE2\/4 subjects. J Lab Clin Med. 2002;140(5):369\u201374.","journal-title":"J Lab Clin Med"},{"issue":"5","key":"15_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00401-014-1266-2","volume":"127","author":"E Martinez-Morillo","year":"2014","unstructured":"Martinez-Morillo E, et al. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer\u2019s disease patients and controls. Acta Neuropathol. 2014;127(5):633\u201343.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"15_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/ana.24326","volume":"77","author":"KL Rasmussen","year":"2015","unstructured":"Rasmussen KL, et al. Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann Neurol. 2015;77(2):301\u201311.","journal-title":"Ann Neurol"},{"issue":"11","key":"15_CR21","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1136\/jnnp-2013-307228","volume":"85","author":"G Berge","year":"2014","unstructured":"Berge G, et al. Apolipoprotein E epsilon2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort. J Neurol Neurosurg Psychiatry. 2014;85(11):1227\u201331.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"15_CR22","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1212\/01.WNL.0000128089.53030.AC","volume":"62","author":"YJ Li","year":"2004","unstructured":"Li YJ, et al. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004;62(11):2005\u20139.","journal-title":"Neurology"},{"issue":"2","key":"15_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/jamaneurol.2013.600","volume":"70","author":"D Tsuang","year":"2013","unstructured":"Tsuang D, et al. APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 2013;70(2):223\u20138.","journal-title":"JAMA Neurol"},{"issue":"3","key":"15_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(10)70325-2","volume":"10","author":"PB Verghese","year":"2011","unstructured":"Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer\u2019s disease and other neurological disorders. Lancet Neurol. 2011;10(3):241\u201352.","journal-title":"Lancet Neurol"},{"key":"15_CR25","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/mds.27297","volume":"33","author":"K Ogaki","year":"2018","unstructured":"Ogaki K, et al. Multiple system atrophy and apolipoprotein E. Mov Disord. 2018;33:647\u201350.","journal-title":"Mov Disord"},{"issue":"1","key":"15_CR26","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1038\/s41467-018-06783-0","volume":"9","author":"N Zhao","year":"2018","unstructured":"Zhao N, et al. APOE epsilon2 is associated with increased tau pathology in primary tauopathy. Nat Commun. 2018;9(1):4388.","journal-title":"Nat Commun"},{"issue":"20","key":"15_CR27","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1093\/hmg\/dds296","volume":"21","author":"C Cruchaga","year":"2012","unstructured":"Cruchaga C, et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer\u2019s disease. Hum Mol Genet. 2012;21(20):4558\u201371.","journal-title":"Hum Mol Genet"},{"issue":"12","key":"15_CR28","doi-asserted-by":"publisher","first-page":"2320 e15-32","DOI":"10.1016\/j.neurobiolaging.2010.04.028","volume":"32","author":"T Darreh-Shori","year":"2011","unstructured":"Darreh-Shori T, et al. Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer\u2019s disease in the brain in vivo. Neurobiol Aging. 2011;32(12):2320 e15-32.","journal-title":"Neurobiol Aging"},{"issue":"45","key":"15_CR29","doi-asserted-by":"publisher","first-page":"11445","DOI":"10.1523\/JNEUROSCI.1972-08.2008","volume":"28","author":"DR Riddell","year":"2008","unstructured":"Riddell DR, et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci. 2008;28(45):11445\u201353.","journal-title":"J Neurosci"},{"issue":"11","key":"15_CR30","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1074\/mcp.M112.018861","volume":"11","author":"R Simon","year":"2012","unstructured":"Simon R, et al. Total ApoE and ApoE4 isoform assays in an Alzheimer\u2019s disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides. Mol Cell Proteomics. 2012;11(11):1389\u2013403.","journal-title":"Mol Cell Proteomics"},{"issue":"6","key":"15_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034078","volume":"7","author":"F Song","year":"2012","unstructured":"Song F, et al. Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS One. 2012;7(6):e34078.","journal-title":"PLoS One"},{"issue":"2","key":"15_CR32","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1021\/pr401060x","volume":"13","author":"E Martinez-Morillo","year":"2014","unstructured":"Martinez-Morillo E, et al. Assessment of peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein e isoforms. J Proteome Res. 2014;13(2):1077\u201387.","journal-title":"J Proteome Res"},{"issue":"1","key":"15_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13195-016-0231-9","volume":"9","author":"HM Nielsen","year":"2017","unstructured":"Nielsen HM, et al. Peripheral apoE isoform levels in cognitively normal APOE epsilon3\/epsilon4 individuals are associated with regional gray matter volume and cerebral glucose metabolism. Alzheimers Res Ther. 2017;9(1):5.","journal-title":"Alzheimers Res Ther"},{"key":"15_CR34","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00401-013-1236-0","volume":"127","author":"JB Toledo","year":"2014","unstructured":"Toledo JB, et al. CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol. 2014;127:621\u201332.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"15_CR35","doi-asserted-by":"publisher","first-page":"13728","DOI":"10.1038\/s41598-017-14204-3","volume":"7","author":"G Koch","year":"2017","unstructured":"Koch G, et al. CSF tau is associated with impaired cortical plasticity, cognitive decline and astrocyte survival only in APOE4-positive Alzheimer\u2019s disease. Sci Rep. 2017;7(1):13728.","journal-title":"Sci Rep"},{"issue":"130","key":"15_CR36","first-page":"1","volume":"6","author":"D Twohig","year":"2018","unstructured":"Twohig D, et al. The relevance of cerebrospinal fluid alpha-synuclein levels to sporadic and familial Alzheimer\u2019s disease. Acta Neuropathol Commun. 2018;6(130):1\u201319.","journal-title":"Acta Neuropathol Commun"},{"key":"15_CR37","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.jalz.2018.06.3053","volume":"14","author":"A Vergallo","year":"2018","unstructured":"Vergallo A, et al. Association of cerebrospinal fluid alpha-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer\u2019s disease biomarkers. Alzheimers Dement. 2018;14:1623\u201331.","journal-title":"Alzheimers Dement"},{"key":"15_CR38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jalz.2018.08.005","volume":"15","author":"DP Veitch","year":"2019","unstructured":"Veitch DP, et al. Understanding disease progression and improving Alzheimer\u2019s disease clinical trials: recent highlights from the Alzheimer\u2019s disease neuroimaging initiative. Alzheimers Dement. 2019;15:106\u201352.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"15_CR39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/ana.21843","volume":"67","author":"JC Morris","year":"2010","unstructured":"Morris JC, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122\u201331.","journal-title":"Ann Neurol"},{"key":"15_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fnagi.2013.00011","volume":"5","author":"SL Risacher","year":"2013","unstructured":"Risacher SL, et al. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci. 2013;5:11.","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"15_CR41","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1212\/WNL.0000000000003585","volume":"88","author":"MJ Grothe","year":"2017","unstructured":"Grothe MJ, et al. Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load. Neurology. 2017;88(6):569\u201376.","journal-title":"Neurology"},{"issue":"10 Pt 2","key":"15_CR42","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1016\/j.neubiorev.2013.10.010","volume":"37","author":"S Suri","year":"2013","unstructured":"Suri S, et al. The forgotten APOE allele: a review of the evidence and suggested mechanisms for the protective effect of APOE varepsilon2. Neurosci Biobehav Rev. 2013;37(10 Pt 2):2878\u201386.","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"15_CR43","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1053\/j.semnuclmed.2017.06.003","volume":"47","author":"CA Mathis","year":"2017","unstructured":"Mathis CA, et al. Small-molecule PET tracers for imaging proteinopathies. Semin Nucl Med. 2017;47(5):553\u201375.","journal-title":"Semin Nucl Med"},{"issue":"2","key":"15_CR44","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/mds.27252","volume":"33","author":"SH Lee","year":"2018","unstructured":"Lee SH, et al. Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases. Mov Disord. 2018;33(2):262\u201372.","journal-title":"Mov Disord"},{"issue":"1","key":"15_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/ana.24825","volume":"81","author":"K Kantarci","year":"2017","unstructured":"Kantarci K, et al. AV-1451 tau and beta-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol. 2017;81(1):58\u201367.","journal-title":"Ann Neurol"},{"issue":"1","key":"15_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13195-018-0403-x","volume":"10","author":"N Mattsson","year":"2018","unstructured":"Mattsson N, et al. Greater tau load and reduced cortical thickness in APOE epsilon4-negative Alzheimer\u2019s disease: a cohort study. Alzheimers Res Ther. 2018;10(1):77.","journal-title":"Alzheimers Res Ther"},{"issue":"Pt 2","key":"15_CR47","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/brain\/awp326","volume":"133","author":"GD Rabinovici","year":"2010","unstructured":"Rabinovici GD, et al. Increased metabolic vulnerability in early-onset Alzheimer\u2019s disease is not related to amyloid burden. Brain. 2010;133(Pt 2):512\u201328.","journal-title":"Brain"},{"issue":"1","key":"15_CR48","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110\u20139.","journal-title":"Ann Neurol"},{"issue":"2","key":"15_CR49","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ana.25142","volume":"83","author":"JL Whitwell","year":"2018","unstructured":"Whitwell JL, et al. [(18) F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer\u2019s disease. Ann Neurol. 2018;83(2):248\u201357.","journal-title":"Ann Neurol"},{"issue":"Pt 5","key":"15_CR50","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139(Pt 5):1551\u201367.","journal-title":"Brain"},{"issue":"19","key":"15_CR51","doi-asserted-by":"publisher","first-page":"10966","DOI":"10.1073\/pnas.1434398100","volume":"100","author":"FM Harris","year":"2003","unstructured":"Harris FM, et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer\u2019s disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A. 2003;100(19):10966\u201371.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"15_CR52","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.neuron.2014.01.045","volume":"81","author":"T Kanekiyo","year":"2014","unstructured":"Kanekiyo T, Xu H, Bu G. ApoE and Abeta in Alzheimer\u2019s disease: accidental encounters or partners? Neuron. 2014;81(4):740\u201354.","journal-title":"Neuron"},{"issue":"6","key":"15_CR53","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ana.21696","volume":"65","author":"E Kok","year":"2009","unstructured":"Kok E, et al. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol. 2009;65(6):650\u20137.","journal-title":"Ann Neurol"},{"key":"15_CR54","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neurobiolaging.2018.07.007","volume":"71","author":"O Pletnikova","year":"2018","unstructured":"Pletnikova O, et al. The spectrum of preclinical Alzheimer\u2019s disease pathology and its modulation by ApoE genotype. Neurobiol Aging. 2018;71:72\u201380.","journal-title":"Neurobiol Aging"},{"issue":"10","key":"15_CR55","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/glia.21004","volume":"58","author":"HM Nielsen","year":"2010","unstructured":"Nielsen HM, et al. Astrocytic Abeta1-42 uptake is determined by Abeta-aggregation state and the presence of amyloid-associated proteins. Glia. 2010;58(10):1235\u201346.","journal-title":"Glia"},{"issue":"4","key":"15_CR56","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/glia.22619","volume":"62","author":"SD Mulder","year":"2014","unstructured":"Mulder SD, et al. Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro. Glia. 2014;62(4):493\u2013503.","journal-title":"Glia"},{"issue":"19","key":"15_CR57","doi-asserted-by":"publisher","first-page":"E1807","DOI":"10.1073\/pnas.1220484110","volume":"110","author":"PB Verghese","year":"2013","unstructured":"Verghese PB, et al. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE\/Abeta association in physiological conditions. Proc Natl Acad Sci U S A. 2013;110(19):E1807\u201316.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"15_CR58","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13024-016-0099-y","volume":"11","author":"Y Fu","year":"2016","unstructured":"Fu Y, et al. Apolipoprotein E lipoprotein particles inhibit amyloid-beta uptake through cell surface heparan sulphate proteoglycan. Mol Neurodegener. 2016;11(1):37.","journal-title":"Mol Neurodegener"},{"issue":"33","key":"15_CR59","doi-asserted-by":"publisher","first-page":"E3138","DOI":"10.1073\/pnas.1301440110","volume":"110","author":"BB Holmes","year":"2013","unstructured":"Holmes BB, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A. 2013;110(33):E3138\u201347.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"15_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094259","volume":"9","author":"M Gassowska","year":"2014","unstructured":"Gassowska M, et al. Extracellular alpha-synuclein leads to microtubule destabilization via GSK-3beta-dependent Tau phosphorylation in PC12 cells. PLoS One. 2014;9(4):e94259.","journal-title":"PLoS One"},{"issue":"1","key":"15_CR61","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0006-8993(91)91092-F","volume":"541","author":"Y Namba","year":"1991","unstructured":"Namba Y, et al. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer\u2019s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541(1):163\u20136.","journal-title":"Brain Res"},{"key":"15_CR62","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.brainres.2012.08.003","volume":"1475","author":"TT Rohn","year":"2012","unstructured":"Rohn TT, et al. Identification of an amino-terminal fragment of apolipoprotein E4 that localizes to neurofibrillary tangles of the Alzheimer\u2019s disease brain. Brain Res. 2012;1475:106\u201315.","journal-title":"Brain Res"},{"issue":"12","key":"15_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080180","volume":"8","author":"TT Rohn","year":"2013","unstructured":"Rohn TT, et al. Immunolocalization of an amino-terminal fragment of apolipoprotein E in the Pick\u2019s disease brain. PLoS One. 2013;8(12):e80180.","journal-title":"PLoS One"},{"issue":"15","key":"15_CR64","doi-asserted-by":"publisher","first-page":"8838","DOI":"10.1073\/pnas.151254698","volume":"98","author":"Y Huang","year":"2001","unstructured":"Huang Y, et al. Apolipoprotein E fragments present in Alzheimer\u2019s disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A. 2001;98(15):8838\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"15_CR65","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1523\/JNEUROSCI.4315-03.2004","volume":"24","author":"WJ Brecht","year":"2004","unstructured":"Brecht WJ, et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci. 2004;24(10):2527\u201334.","journal-title":"J Neurosci"},{"issue":"3","key":"15_CR66","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/BF02829548","volume":"26","author":"J Zhou","year":"2006","unstructured":"Zhou J, Chen J, Feng Y. Effect of truncated-ApoE4 overexpression on tau phosphorylation in cultured N2a cells. J Huazhong Univ Sci Technolog Med Sci. 2006;26(3):272\u20134.","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"issue":"3","key":"15_CR67","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0002-9440(10)64963-2","volume":"156","author":"I Tesseur","year":"2000","unstructured":"Tesseur I, et al. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol. 2000;156(3):951\u201364.","journal-title":"Am J Pathol"},{"issue":"7673","key":"15_CR68","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549(7673):523\u20137.","journal-title":"Nature"},{"issue":"8","key":"15_CR69","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"Antoine Leuzy","year":"2019","unstructured":"Leuzy A, et al. Tau PET imaging in neurodegenerative tauopathies\u2014still a challenge. Mol Psychiatry. 2019;24(8):1112\u201334.","journal-title":"Molecular Psychiatry"}],"container-title":["Advances in Experimental Medicine and Biology","Tau Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-32-9358-8_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T01:11:46Z","timestamp":1722474706000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-981-32-9358-8_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9789813293571","9789813293588"],"references-count":69,"URL":"https:\/\/doi.org\/10.1007\/978-981-32-9358-8_15","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"25 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}